WIN-Partners Co (TSE:3183) EBIT: 円3,021 Mil (TTM As of Mar. 2026)


TSE:3183 WIN-Partners Co Ltd TSE:3183
63 GF Score
Price 円1,285.00
GF Value 円1,522.55
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is WIN-Partners Co EBIT?

WIN-Partners Co TSE:3183 +0.31% 63 EBIT is 円3,021 Mil as of Mar. 2026. GuruFocus rates TSE:3183 with a GF Score™ of 63/100 and a GF Value™ of 円1,522.55 (Modestly Undervalued). The stock has 3 warning signs investors should review.

WIN-Partners Co's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2026 was 円1,555 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was 円3,021 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. WIN-Partners Co's annualized ROC % for the quarter that ended in Mar. 2026 was 16.46%. WIN-Partners Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 51.47%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. WIN-Partners Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 15.02%.

WIN-Partners Co  (TSE:3183) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

WIN-Partners Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=3109.146 * ( 1 - 30.45% )/( (12206.248 + 14071.439)/ 2 )
=2162.411043/13138.8435
=16.46 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=46525.896 - 18298.46 - ( 16021.188 - max(0, 21885.838 - 39727.257+16021.188))
=12206.248

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=50632.099 - 20628.917 - ( 15931.743 - max(0, 25245.432 - 42862.145+15931.743))
=14071.439

Note: The Operating Income data used here is two times the semi-annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

WIN-Partners Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=3109.146/( ( (4365.819 + max(1820.231, 0)) + (4525.791 + max(1368.629, 0)) )/ 2 )
=3109.146/( ( 6186.05 + 5894.42 )/ 2 )
=3109.146/6040.235
=51.47 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(16096.731 + 3501.891 + 4107.447) - (18298.46 + 0 + 3587.378)
=1820.231

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(18525.957 + 3922.118 + 4165.986) - (20628.917 + 0 + 4616.515)
=1368.629

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

WIN-Partners Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=3020.762/20117.325
=15.02 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

WIN-Partners Co EBIT Related Terms

WIN-Partners Co EBIT Historical Data

* Premium members only.

The historical data trend for WIN-Partners Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

WIN-Partners Co EBIT Chart

WIN-Partners Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,654.85 2,944.93 2,720.42 2,808.40 3,020.76

WIN-Partners Co Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,678.70 1,247.53 1,560.87 1,466.19 1,554.57

TSE:3183 vs MCK, CAH, COR: EBIT Comparison

For the Medical Distribution subindustry, WIN-Partners Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

WIN-Partners Co EV-to-EBIT vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, WIN-Partners Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where WIN-Partners Co's EV-to-EBIT falls into.


TSE:3183
63GF Score
WIN-Partners Co Ltd TSE:3183
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

WIN-Partners Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円3,021 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of 円3,021 Mil mean?
WIN-Partners Co (TSE:3183) has a EBIT of 円3,021 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on WIN-Partners Co.
Is WIN-Partners Co's EBIT too high?
WIN-Partners Co's current EBIT is 円3,021 Mil. Overall, WIN-Partners Co has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does WIN-Partners Co's EBIT compare to MCK and CAH?
WIN-Partners Co's EBIT of 円3,021 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Distribution company?
A good EBIT depends on the Medical Distribution industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on WIN-Partners Co. WIN-Partners Co's current EBIT is 円3,021 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WIN-Partners Co stock overvalued right now?
Based on GuruFocus' analysis, WIN-Partners Co (TSE:3183) is currently considered Modestly Undervalued. The stock's GF Value™ is 円1,522.55, compared to a current price of 円1,285.00 — trading 15.6% below its estimated fair value. The current EBIT is 円3,021 Mil. WIN-Partners Co's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For WIN-Partners Co (TSE:3183), the current EBIT is 円3,021 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is WIN-Partners Co (TSE:3183) Overvalued in 2026?

Based on GuruFocus' analysis, WIN-Partners Co stock appears to be undervalued. The current stock price of 円1,285.00 is trading 15.6% below its estimated GF Value™ of 円1,522.55. GuruFocus considers WIN-Partners Co to be Modestly Undervalued.

Key valuation signals for TSE:3183:

  • EBIT: 円3,021 Mil
  • GF Value™: 円1,522.55 vs. price of 円1,285.00 (15.6% below fair value)
  • GF Score™: 63/100 with 3 warning signs

No single metric tells the full story. See the TSE:3183 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

WIN-Partners Co Business Description

Address 2-2-1 Kyobashi, Chuoku, 21st Floor, Kyobashi Edogrand, Tokyo, JPN, 104-0031
WIN-Partners Co Ltd is engaged in the healthcare sector. The company provides medical devices to Japan's medical institutions. Its products offerings are Cardiovascular device, Insulin Pump, X-ray Angio System, Carotid Artery Stent, Stent Graft, among others. The company operates only in one segment which is the medical equipment sales business.
63GF Score

Get the complete analysis for TSE:3183

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,285.00
Price
円1,522.55
GF Value